


**SYNERGY
MEGATRON™**
Everolimus-Eluting Platinum Chromium Coronary Stent System



Purpose Built for
LARGE
Proximal Vessels
Mega Strength, Optimal Healing.



Best-in-Class Axial & Radial Strength

Bench tests performed by Boston Scientific Corporation



43%
More axial strength*


Compared to Resolute Onyx

To maintain stent integrity
in complex interventions

44%
More axial strength
than Xience Sierra*

225%

More axial strength
than Ultimaster Nagomi*
(2-connector design stent)



40%
More radial strength*


Compared to Resolute Onyx

To maintain vessel patency
and maximize the MSA

60%
More radial strength
than Xience Sierra*

74%

More radial strength
than Ultimaster Nagomi*
(10-Peak Design Stent)





Unmatched 3.5, 4.0, 4.5, 5.0 Overexpansion

Compared to Resolute Onyx & Onyx Frontier

A versatile stent model that can expand from

3.5 mm to 6.0 mm

for tapered vessels, bifurcations and proximal
optimization technique (POT)



Labeled Nominal: —
Labeled Post-Dil Limit: - - -

* SYNERGY MEGATRON 5.0 mm diameter vs. Resolute Onyx 5.0 mm diameter. (N=3 minimum), SYNERGY MEGATRON 4.0 mm vs. Xience Sierra 4.0 mm diameter (N=3 minimum) and vs. Nagomi 4.0 mm (N=3 minimum). Bench tests performed by Boston Scientific Corporation. Data on file. Bench test results not necessarily indicative of clinical performance. † Expansion information pulled from individual IFU documents for: SYNERGY MEGATRON Stent System, SYNERGY Stent System, Resolute Onyx & Onyx Frontier Stent System, Xience Sierra & Xience Skypoint Stent System, Ultimaster Nagomi Stent System, Osiro Mission Stent System.

SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY MEGATRON is purpose built for large proximal vessels, including left main, bifurcations and ostial lesions such as the ostial LAD, LCx and RCA. Available in 3.5 mm–5.0 mm diameters to maximize performance where it is needed most.

Product Features

- ⬡ Best-in-Class Radial and Axial Strength*
- ⬡ 3.5 to 6.0mm Overexpansion†
- ⬡ Maximum Visibility‡
- ⬡ Uniform Lesion Scaffolding§


Based on bench testing

Trusted Bioabsorbable Polymer

- ⬡ Early Healing
- ⬡ Consistently Low ST Rates
- ⬡ Short DAPT as short as 1-month in HBR Patients
- ⬡ Proven Long-Term Outcomes

Clinical Benefits


- Higher Strength for Proximal, ⬡
Fibrotic & Calcified Lesions
- Accommodates Wide Diameter Mismatch ⬡
- Better Placement Accuracy* ⬡
- Maximizes Lumen Gain ⬡



* Mauro, M.A. et al. (2013) Image-Guided Interventions (2nd ed.), Saunders/Elsevier.

Maximum Visibility


Platinum Chromium (PtCr) Alloy
enhances visibility to aid in accurate
stent placement




SYNERGY MEGATRON
BP Stent*

Resolute Onyx
PP Stent

Xience Sierra
PP Stent




Uniform Lesion Scaffolding




20%
Less
Tissue
Prolapse

12-peak stent design to minimize
tissue prolapse and maintain
lumen diameter†



Large Side Branch Expansion

Allows for effective treatment of bifurcations



5.0 mm Maximum
expanded cell diameter‡

* 3.5 mm stent products tested under 6.0 mm copper phantom to simulate body mass. Bench testing performed by Boston Scientific Corporation. Data on file. Bench test results not necessarily indicative of clinical performance.

† Bench testing performed by Boston Scientific Corporation. Data on file. Bench test and computational model results not necessarily indicative of clinical performance.

‡ Based on SYNERGY MEGATRON 5.0 mm diameter. Bench testing performed by Boston Scientific Corporation. Data on file. Bench test results not necessarily indicative of clinical performance.

MULTI-VESSEL DISEASE UNSTABLE ANGINA

CE MARK ACUTE CORONARY SYNDROME
OSTIAL LESIONS

BIFURCATION
HIGH BLEEDING RISK*
LEFT MAIN
INDICATIONS

IN-STENT RESTENOSIS

SAPHENOUS
VEIN GRAFT

DAPT AS SHORT AS 1-MONTH*

RENAL FAILURE

*SYNERGY MEGATRON Stent System is intended for treatment of patients at high risk of bleeding with as short as one month of dual antiplatelet therapy (DAPT).


Boston Scientific now offers a portfolio of SYNERGY BP Stents designed to optimize performance and enable early healing in every type of case.

HEAL
WITH CONFIDENCE

SYNERGY

MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System



**Average stent crossing profile measured on the SYNERGY MEGATRON 3.50 mm diameter.

Ø (mm)	Stent Length (mm)							Overexpansion Capabilities
	8	12	16	20	24	28	32	
3.50	H7493942708350	H7493942712350	H7493942716350	H7493942720350	H7493942724350	H7493942728350	H7493942732350	6.0
4.00	H7493942708400	H7493942712400	H7493942716400	H7493942720400	H7493942724400	H7493942728400	H7493942732400	6.0
4.50	H7493942708450	H7493942712450	H7493942716450	H7493942720450	H7493942724450	H7493942728450	H7493942732450	6.0
5.00	H7493942708500	H7493942712500	H7493942716500	H7493942720500	H7493942724500	H7493942728500	H7493942732500	6.0

Boston
Scientific

Advancing science for life™

All cited trademarks are the property of their respective owners.
Please review the full IFU for indications for use and operating instructions.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

www.bostonscientific.eu
© 2026 Boston Scientific Corporation or
its affiliates. All rights reserved.
IC-705302-AD

C € 0344